Table 1.
Comparison between SPRY4‐IT1 expression and clinical characteristics
| Variables | No. (n = 70) N (%) | SPRY‐IT1 expressionb | P * | |
|---|---|---|---|---|
| Low expression (n = 38) N (%) | High expression (n = 32) N (%) | |||
| Sex | ||||
| Male | 45 (64.3) | 26 (68.4) | 19 (59.4) | 0.431 |
| Female | 25 (35.7) | 12 (31.6) | 13 (40.6) | |
| Age (years) | ||||
| < 60 | 42 (60.0) | 24 (63.2) | 18 (56.3) | 0.557 |
| ≥ 60 | 28 (40.0) | 14 (36.8) | 14 (43.7) | |
| Tumor site | ||||
| Extremities | 23 (32.9) | 18 (47.4) | 5 (15.6) | 0.019 |
| Trunk | 37 (52.9) | 16 (42.1) | 21 (65.6) | |
| Head and neck | 10 (14.3) | 4 (10.5) | 6 (18.8) | |
| Histologic type | ||||
| Superficial spreading | 39 (55.7) | 21 (55.3) | 18 (56.3) | 0.934 |
| Nodular | 31 (44.3) | 17 (44.7) | 14 (43.7) | |
| Tumor stagea | ||||
| I–II | 32 (45.7) | 28 (73.7) | 4 (12.5) | < 0.001 |
| III | 25 (35.7) | 7 (18.4) | 18 (56.3) | |
| IV | 13 (18.9) | 3 (7.9) | 10 (31.3) | |
*Two‐side chi‐square test.
aTumor stage system according to AJCC classification.
bLow and high SPRY4‐IT1 groups were split by the cutoff value 2.64.